CAS NO: | 1276105-89-5 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | CNX-1351 is a potent and isoform-selective targeted covalentPI3Kαinhibitor withIC50of 6.8 nM. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | CNX-1351 is able to potently (EC50<100 nm) and specifically inhibit signaling in pi3kα-dependent cancer cell lines, this leads to a potent antiproliferative effect (gi50<100 nm). cnx-1351 inhibits pi3k signaling in skov3 cells, with potency (ec50of 10-100 nM) similar to that of the pan-PI3K inhibitor. To investigate the functional consequence of inhibiting PI3Kα in cells, two cell lines with differentPIK3CAactivating mutations, SKOV3 ovarian cancer cells (H1047R) and MCF-7 breast cancer cells (E545K), are treated with CNX-1351 and growth is monitored. BothPIK3CA-driven cell lines are growth inhibited by exposure to CNX-1351 for 96 h (GI50of 78 and 55 nM, respectively)[1]. | ||||||||||||||||
体内研究 (In Vivo) | CNX-1351 inhibits p-AktSer473in mouse spleens and bonds to PI3Kα in vivo. CNX-1351 is delivered into the intraperitoneal cavity of nude mice at 100 mg/kg once a day for 5 consecutive days (n=3 mice per group). Spleens are harvested from the mice at the indicated times after the last dose (1-24 h) and interrogated by immunoblot for P-AktSer473or for PI3Kα occupancy. Inhibition of PI3K signaling is detected as a decrease in P-AktSer473at 1 and 4 h after last dose[1]. | ||||||||||||||||
分子量 | 573.71 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C30H35N7O3S | ||||||||||||||||
CAS 号 | 1276105-89-5 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(174.30 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|